FDA backs Roche Gazyva in first-line follicular lymphoma
ZURICH: The U.S. Food and Drug Administration on Thursday expanded approvals for Roche's Gazyva to include previously untreated follicular lymphoma, bolstering the Swiss drugmaker's efforts to strengthen its portfolio of blood cancer medicines.
Gazyva is a follow-on drug to Rituxan, which at more than $7 billion in annual sales is Roche's top seller but which has lost patent protection in Europe, exposing it to cheaper copies.
(Reporting by John Miller, editing by David Evans)
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd